Semaglutide vs Tirzepatide vs Retatrutide
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| What it is | Approved medicine for diabetes and obesity that imitates the hormone GLP-1 to help control blood sugar and body weight. | Approved medicine for diabetes and obesity that imitates two hormones, GIP and GLP-1. | Not-yet-approved weight-loss medicine in late-stage trials that imitates several hormones, including GLP-1. |
| Type | GLP-1 receptor agonist | GIP/GLP-1 dual agonist | Tri-agonist (GIP/GLP-1/Gcgr) |
| Structure | 31 aa, GLP-1 analog | 39 aa, lipidated peptide (Eli Lilly) | 39 aa, lipidated peptide (Eli Lilly) |
| Status | FDA approved | — | — |
| Route | SC, once weekly | — | — |
| Storage | 2–8°C | 2–8°C (reconstituted) | 2–8°C (reconstituted) |
| Molecular weight | — | ~4814 Da | ~4824 Da |
| Target area | — | T2DM, obesity | Weight loss, T2DM |
| Stability | — | ~30 days (reconstituted) | ~28 days (reconstituted) |
| Full entry | Open → | Open → | Open → |
Semaglutide, tirzepatide or retatrutide: what separates them?
All three act on the same gut-hormone system, just at a growing number of points. Semaglutide targets one of those signals, GLP-1; tirzepatide adds GIP to it; retatrutide acts on three, GIP, GLP-1 and glucagon. This shows up in the trial data: in the direct comparison of semaglutide and tirzepatide, it was the tirzepatide group that reached the larger reduction in body weight. Approval runs the other way: semaglutide and tirzepatide are licensed for type 2 diabetes and obesity; retatrutide is still in trials.


